Psychedelic Retreat Shows Promise for PTSD Treatment, But Raises Concerns
Nine US military veterans with PTSD participated in a psychedelic retreat in Mexico using psilocybin and 5-MeO-DMT in March; eight reported significant symptom improvement, while one experienced negative effects; the Department of Veterans Affairs is conducting clinical trials to explore the potenti...
Psychedelic Retreat Shows Promise for PTSD Treatment, But Raises Concerns
Nine US military veterans with PTSD participated in a psychedelic retreat in Mexico using psilocybin and 5-MeO-DMT in March; eight reported significant symptom improvement, while one experienced negative effects; the Department of Veterans Affairs is conducting clinical trials to explore the potenti...
Progress
40% Bias Score
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
mRNA Cancer Vaccines: Promising Trials, but No Approvals Yet
Despite initial hopes after the success of mRNA COVID-19 vaccines, no mRNA cancer vaccines have received approval yet; however, several are in clinical trials, showing potential for personalized cancer treatments but facing significant hurdles.
Progress
32% Bias Score
NIH Research Halted by Trump Administration's Communications Pause
The Trump administration's communications pause has blocked purchasing at the NIH, halting essential supplies for research and jeopardizing ongoing studies; researchers fear contract renewals will also be affected, creating further instability.
NIH Research Halted by Trump Administration's Communications Pause
The Trump administration's communications pause has blocked purchasing at the NIH, halting essential supplies for research and jeopardizing ongoing studies; researchers fear contract renewals will also be affected, creating further instability.
Progress
44% Bias Score
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
Progress
40% Bias Score
18th-Century Trial Proposal Foreshadowed Modern Clinical Research
New research suggests Francis Hauksbee the Younger's 1743 proposal for a controlled clinical trial design, though never conducted, may have influenced James Lind's 1747 scurvy trial, marking a critical early step in the evolution of evidence-based medicine.
18th-Century Trial Proposal Foreshadowed Modern Clinical Research
New research suggests Francis Hauksbee the Younger's 1743 proposal for a controlled clinical trial design, though never conducted, may have influenced James Lind's 1747 scurvy trial, marking a critical early step in the evolution of evidence-based medicine.
Progress
24% Bias Score
NIH's $1.8 Billion Long COVID Investment: Slow Progress Fuels Patient Frustration
The NIH has invested $1.8 billion in long COVID research, yet millions of patients lack effective treatments, prompting calls for faster clinical trials and FDA approvals; research focuses on understanding the disease's mechanisms before large-scale trials.
NIH's $1.8 Billion Long COVID Investment: Slow Progress Fuels Patient Frustration
The NIH has invested $1.8 billion in long COVID research, yet millions of patients lack effective treatments, prompting calls for faster clinical trials and FDA approvals; research focuses on understanding the disease's mechanisms before large-scale trials.
Progress
60% Bias Score
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
Progress
48% Bias Score
NIH Clarifies Research Continuity Amidst Communications Pause
NIH Acting Director Matthew Memoli issued a memo clarifying that clinical trials and essential research can proceed despite a temporary communications pause ordered by President Trump, but new grant reviews and procurements for new studies are temporarily halted.
NIH Clarifies Research Continuity Amidst Communications Pause
NIH Acting Director Matthew Memoli issued a memo clarifying that clinical trials and essential research can proceed despite a temporary communications pause ordered by President Trump, but new grant reviews and procurements for new studies are temporarily halted.
Progress
44% Bias Score
Modified Bird Virus Shows Promise in Treating Multiple Cancers
A Chinese study showed a modified bird virus, NDV-GT, shrunk or stopped tumor growth in 22 of 23 patients with eight different advanced cancers in a trial; further trials are planned.
Modified Bird Virus Shows Promise in Treating Multiple Cancers
A Chinese study showed a modified bird virus, NDV-GT, shrunk or stopped tumor growth in 22 of 23 patients with eight different advanced cancers in a trial; further trials are planned.
Progress
40% Bias Score
18th Century Trial Proposal Foreshadowed Modern Clinical Research
Francis Hauksbee the Younger's 1743 proposal for a controlled trial design to test venereal disease treatments, predating James Lind's scurvy trial by a decade, reveals a surprisingly modern approach to medical research that was likely influential on Lind's work, though Hauksbee's proposal was never...
18th Century Trial Proposal Foreshadowed Modern Clinical Research
Francis Hauksbee the Younger's 1743 proposal for a controlled trial design to test venereal disease treatments, predating James Lind's scurvy trial by a decade, reveals a surprisingly modern approach to medical research that was likely influential on Lind's work, though Hauksbee's proposal was never...
Progress
40% Bias Score
18th-Century Trial Proposal Foreshadowed Modern Clinical Research
New research suggests Francis Hauksbee the Younger's 1743 proposal for a controlled clinical trial, though never conducted, may have influenced James Lind's 1747 scurvy trial, marking a pivotal moment in the evolution of modern clinical research.
18th-Century Trial Proposal Foreshadowed Modern Clinical Research
New research suggests Francis Hauksbee the Younger's 1743 proposal for a controlled clinical trial, though never conducted, may have influenced James Lind's 1747 scurvy trial, marking a pivotal moment in the evolution of modern clinical research.
Progress
28% Bias Score
Groundbreaking Clinical Trials Anticipated in 2025
In 2025, several groundbreaking clinical trials will release preliminary data, including a large-scale US dietary study employing AI analysis (8,000+ adults), Oxford University's CBD trial for psychosis (1,000 patients), and research on personalized cancer vaccines.
Groundbreaking Clinical Trials Anticipated in 2025
In 2025, several groundbreaking clinical trials will release preliminary data, including a large-scale US dietary study employing AI analysis (8,000+ adults), Oxford University's CBD trial for psychosis (1,000 patients), and research on personalized cancer vaccines.
Progress
12% Bias Score